Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution
Menu

Contact Us
If you have any questions or feedback please contact us.
 Back to Profile

Elaine Lam

Concepts (249)

Concepts are derived automatically from a person's publications.

Cloud
Categories
Timeline
Details
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.

Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Carcinoma, Renal Cell
30
2024
168
6.710
 Why?
Kidney Neoplasms
33
2024
326
6.340
 Why?
Prostatic Neoplasms
13
2023
927
3.230
 Why?
Neoplasms, Germ Cell and Embryonal
3
2023
60
1.630
 Why?
Antineoplastic Agents
13
2023
1893
1.370
 Why?
Prostate-Specific Antigen
4
2023
151
1.280
 Why?
Neoplasms
10
2023
2118
1.150
 Why?
Antineoplastic Combined Chemotherapy Protocols
14
2023
1361
1.140
 Why?
Protein Kinase Inhibitors
11
2021
790
1.040
 Why?
Antibodies, Monoclonal, Humanized
9
2023
667
1.030
 Why?
Testicular Neoplasms
3
2023
95
1.020
 Why?
Seminoma
2
2021
17
0.880
 Why?
Carcinoma, Medullary
2
2013
13
0.810
 Why?
Retroperitoneal Neoplasms
1
2021
22
0.760
 Why?
Antineoplastic Agents, Immunological
1
2023
154
0.760
 Why?
Male
52
2024
55968
0.730
 Why?
Teratoma
1
2021
92
0.720
 Why?
Aged
30
2024
19255
0.720
 Why?
Pneumocystis carinii
1
2020
7
0.710
 Why?
Spinal Cord Compression
1
2020
17
0.710
 Why?
Pneumonia, Pneumocystis
1
2020
27
0.700
 Why?
Trimethoprim, Sulfamethoxazole Drug Combination
1
2020
39
0.700
 Why?
Euterpe
1
2018
5
0.640
 Why?
Pyrazoles
3
2022
362
0.620
 Why?
Prednisone
3
2020
232
0.600
 Why?
TWEAK Receptor
1
2017
5
0.600
 Why?
Humans
71
2024
115613
0.600
 Why?
Sulfonamides
3
2015
447
0.590
 Why?
Abiraterone Acetate
1
2017
14
0.570
 Why?
Neoplasm Recurrence, Local
3
2023
863
0.570
 Why?
Plant Extracts
1
2018
153
0.560
 Why?
Middle Aged
31
2024
27014
0.550
 Why?
Pyridines
4
2021
425
0.550
 Why?
Brain Neoplasms
2
2021
980
0.550
 Why?
Adrenal Cortex Hormones
1
2020
509
0.540
 Why?
Neoplasm Metastasis
9
2020
526
0.540
 Why?
Antineoplastic Agents, Hormonal
2
2015
139
0.530
 Why?
Carcinoma, Papillary
1
2015
73
0.500
 Why?
Paclitaxel
3
2022
192
0.480
 Why?
Prostatic Neoplasms, Castration-Resistant
3
2022
40
0.470
 Why?
Interleukin-2
2
2014
417
0.460
 Why?
Antibodies, Monoclonal
2
2017
1265
0.460
 Why?
Neoplasms, Complex and Mixed
1
2013
7
0.450
 Why?
Biomarkers, Tumor
5
2016
1048
0.440
 Why?
Retrospective Studies
17
2024
12608
0.430
 Why?
Carcinoma, Transitional Cell
2
2023
54
0.430
 Why?
Nephrectomy
4
2024
150
0.400
 Why?
Epothilones
1
2011
1
0.390
 Why?
Androgen Antagonists
3
2020
69
0.390
 Why?
Angiomyolipoma
1
2011
18
0.390
 Why?
Deoxycytidine
2
2010
140
0.380
 Why?
Multicenter Studies as Topic
1
2012
249
0.380
 Why?
Treatment Outcome
14
2022
9159
0.370
 Why?
Anilides
4
2021
67
0.370
 Why?
Aged, 80 and over
12
2024
6419
0.370
 Why?
Urinary Bladder Neoplasms
2
2023
197
0.370
 Why?
Benzenesulfonates
1
2010
21
0.360
 Why?
Suramin
1
2010
6
0.350
 Why?
Radiosurgery
3
2019
298
0.340
 Why?
Immunotherapy
5
2024
479
0.330
 Why?
Patient Reported Outcome Measures
3
2020
250
0.330
 Why?
Maximum Tolerated Dose
6
2022
182
0.330
 Why?
Fluorouracil
1
2008
151
0.300
 Why?
Bone Neoplasms
2
2023
194
0.300
 Why?
Adult
21
2024
30726
0.290
 Why?
Neoplasm Staging
7
2017
1178
0.290
 Why?
Chemotherapy, Adjuvant
3
2013
334
0.280
 Why?
Quinazolines
1
2008
241
0.280
 Why?
Thyroid Neoplasms
1
2010
262
0.280
 Why?
Lung Neoplasms
3
2020
2207
0.270
 Why?
Carcinoma, Non-Small-Cell Lung
2
2015
963
0.270
 Why?
Prognosis
5
2023
3339
0.270
 Why?
Drug Administration Schedule
3
2021
724
0.260
 Why?
Female
27
2024
59932
0.260
 Why?
Sulfones
2
2017
98
0.250
 Why?
Phenylurea Compounds
4
2016
83
0.250
 Why?
Ipilimumab
2
2021
28
0.230
 Why?
Benzoxazoles
2
2022
16
0.230
 Why?
Taxoids
2
2017
94
0.220
 Why?
Platinum
1
2023
40
0.220
 Why?
Bevacizumab
2
2020
118
0.210
 Why?
Disease Progression
2
2021
2418
0.210
 Why?
Mastectomy
1
2023
99
0.210
 Why?
Pyrimidines
3
2022
376
0.210
 Why?
Remission, Spontaneous
1
2021
37
0.190
 Why?
Biliary Tract Neoplasms
1
2021
20
0.190
 Why?
Celecoxib
2
2012
38
0.180
 Why?
Neoplasm, Residual
1
2021
105
0.180
 Why?
Phosphatidylinositol 3-Kinases
1
2022
332
0.180
 Why?
Carboplatin
1
2021
139
0.180
 Why?
Syndrome
1
2021
339
0.180
 Why?
Proto-Oncogene Proteins c-akt
1
2022
400
0.180
 Why?
Combined Modality Therapy
4
2019
1127
0.180
 Why?
Thrombosis
1
2023
302
0.170
 Why?
Urologic Neoplasms
1
2020
25
0.170
 Why?
Azepines
1
2020
74
0.170
 Why?
TOR Serine-Threonine Kinases
1
2022
362
0.170
 Why?
Antiemetics
1
2020
32
0.170
 Why?
Cancer Care Facilities
1
2020
30
0.170
 Why?
Liver Neoplasms
1
2023
521
0.170
 Why?
Homologous Recombination
1
2019
21
0.170
 Why?
Morpholines
1
2020
103
0.170
 Why?
Fatal Outcome
1
2020
286
0.160
 Why?
MAP Kinase Kinase Kinases
1
2019
68
0.160
 Why?
Disease-Free Survival
4
2016
621
0.160
 Why?
Fruit and Vegetable Juices
1
2018
11
0.160
 Why?
Kaplan-Meier Estimate
4
2016
815
0.160
 Why?
Drug Hypersensitivity
1
2020
86
0.160
 Why?
Cost-Benefit Analysis
1
2021
548
0.150
 Why?
Neoplastic Cells, Circulating
2
2016
59
0.150
 Why?
Indans
1
2017
9
0.150
 Why?
Interferon beta-1b
1
2017
2
0.150
 Why?
Niacinamide
3
2016
65
0.150
 Why?
Cell Line, Tumor
3
2020
2751
0.140
 Why?
Neoadjuvant Therapy
2
2023
301
0.140
 Why?
Nanoparticles
1
2021
316
0.140
 Why?
Proton Therapy
1
2017
10
0.140
 Why?
Administration, Oral
3
2022
734
0.140
 Why?
DNA Damage
1
2019
357
0.140
 Why?
Erythrocytes, Abnormal
1
2016
13
0.140
 Why?
Autoimmune Diseases
1
2020
395
0.140
 Why?
Dose-Response Relationship, Drug
3
2022
1870
0.140
 Why?
Multiple Sclerosis, Relapsing-Remitting
1
2017
69
0.140
 Why?
Hematologic Diseases
1
2016
57
0.130
 Why?
Oncolytic Virotherapy
1
2015
8
0.130
 Why?
Indazoles
2
2015
58
0.130
 Why?
Basic Helix-Loop-Helix Transcription Factors
1
2017
225
0.130
 Why?
Mammalian orthoreovirus 3
1
2015
34
0.130
 Why?
Fatigue
2
2022
296
0.130
 Why?
Pyrroles
1
2016
185
0.130
 Why?
Angiopoietin-1
1
2015
10
0.130
 Why?
Angiopoietin-2
1
2015
12
0.130
 Why?
Magnetic Resonance Imaging
2
2021
3071
0.130
 Why?
Receptor, IGF Type 1
1
2015
58
0.120
 Why?
Imidazoles
2
2015
217
0.120
 Why?
Kidney Glomerulus
1
2015
102
0.120
 Why?
Proto-Oncogene Proteins p21(ras)
1
2015
228
0.120
 Why?
Soft Tissue Neoplasms
1
2015
90
0.120
 Why?
Practice Guidelines as Topic
2
2020
1405
0.120
 Why?
Radiation Tolerance
1
2015
92
0.120
 Why?
Indoles
1
2016
309
0.120
 Why?
Receptors, Vascular Endothelial Growth Factor
2
2013
104
0.110
 Why?
Patient Satisfaction
1
2017
585
0.110
 Why?
Glycine
1
2014
156
0.110
 Why?
Prostatectomy
1
2013
98
0.110
 Why?
Multiple Sclerosis
1
2017
380
0.100
 Why?
Glomerular Filtration Rate
1
2015
605
0.100
 Why?
Recombinant Fusion Proteins
1
2015
616
0.100
 Why?
Quinolines
1
2013
129
0.100
 Why?
Breast Neoplasms
1
2023
1872
0.100
 Why?
Tubulin Modulators
1
2011
9
0.100
 Why?
Metabolic Clearance Rate
1
2011
108
0.100
 Why?
Clinical Trials as Topic
1
2015
941
0.090
 Why?
Arthralgia
1
2011
50
0.090
 Why?
Area Under Curve
1
2011
278
0.090
 Why?
Cohort Studies
4
2021
4945
0.090
 Why?
Anti-Bacterial Agents
1
2020
1485
0.090
 Why?
Mechanistic Target of Rapamycin Complex 1
2
2022
99
0.090
 Why?
Survival Rate
3
2020
1650
0.090
 Why?
Peripheral Nervous System Diseases
1
2011
120
0.090
 Why?
Diarrhea
1
2011
173
0.090
 Why?
Proto-Oncogene Proteins c-ret
1
2010
24
0.090
 Why?
Molecular Structure
1
2011
447
0.090
 Why?
Biopsy
1
2013
1056
0.090
 Why?
Nomograms
1
2010
42
0.080
 Why?
Radiotherapy, Adjuvant
1
2010
182
0.080
 Why?
Drug Synergism
1
2010
317
0.080
 Why?
Immunohistochemistry
1
2013
1642
0.080
 Why?
Quality of Life
1
2020
2387
0.080
 Why?
Infusions, Intravenous
1
2010
374
0.080
 Why?
Capecitabine
1
2008
46
0.080
 Why?
Positron-Emission Tomography
1
2010
284
0.080
 Why?
Melanoma
1
2014
651
0.070
 Why?
Follow-Up Studies
3
2020
4440
0.070
 Why?
Tomography, X-Ray Computed
2
2022
2392
0.070
 Why?
Risk
1
2008
819
0.070
 Why?
Risk Factors
2
2020
8699
0.060
 Why?
Cytoreduction Surgical Procedures
1
2024
40
0.060
 Why?
Prospective Studies
3
2021
6264
0.060
 Why?
Young Adult
3
2020
10487
0.060
 Why?
Cardiovascular Diseases
1
2014
1724
0.050
 Why?
Mastectomy, Segmental
1
2023
76
0.050
 Why?
Disease Management
2
2017
563
0.050
 Why?
Cisplatin
1
2023
263
0.050
 Why?
Nephritis, Interstitial
1
2020
7
0.040
 Why?
International Agencies
1
2020
29
0.040
 Why?
Aurora Kinase A
1
2020
51
0.040
 Why?
Lymphocytes
1
2022
344
0.040
 Why?
Drug Evaluation
1
2020
79
0.040
 Why?
Mechanistic Target of Rapamycin Complex 2
1
2020
57
0.040
 Why?
Medical Oncology
1
2022
230
0.040
 Why?
Time Factors
1
2010
6165
0.040
 Why?
Nausea
1
2020
103
0.040
 Why?
Mutation
1
2010
3364
0.040
 Why?
Lymphatic Metastasis
1
2020
276
0.040
 Why?
Vomiting
1
2020
125
0.040
 Why?
Hospitals
1
2023
585
0.040
 Why?
United States
2
2017
12297
0.040
 Why?
B7-H1 Antigen
1
2020
139
0.040
 Why?
Central Nervous System
1
2020
239
0.040
 Why?
Databases, Factual
1
2023
1138
0.040
 Why?
Genetic Testing
1
2020
382
0.040
 Why?
Xenograft Model Antitumor Assays
1
2020
704
0.040
 Why?
Retreatment
1
2017
70
0.040
 Why?
Drug Therapy, Combination
1
2020
962
0.040
 Why?
Academic Medical Centers
1
2020
414
0.040
 Why?
National Cancer Institute (U.S.)
1
2017
40
0.040
 Why?
Clinical Decision-Making
1
2019
273
0.040
 Why?
Receptor Protein-Tyrosine Kinases
1
2019
225
0.040
 Why?
Erythrocyte Indices
1
2016
27
0.030
 Why?
Anti-Inflammatory Agents
1
2020
448
0.030
 Why?
Neutrophils
1
2022
1172
0.030
 Why?
Drug-Related Side Effects and Adverse Reactions
1
2019
242
0.030
 Why?
Drug Resistance, Neoplasm
1
2020
638
0.030
 Why?
Abdominal Neoplasms
1
2015
26
0.030
 Why?
Thoracic Neoplasms
1
2015
33
0.030
 Why?
Tosyl Compounds
1
2015
14
0.030
 Why?
Antibodies, Neoplasm
1
2015
30
0.030
 Why?
Kidney Function Tests
1
2015
141
0.030
 Why?
Neoplasm Grading
1
2015
244
0.030
 Why?
Angiogenesis Inhibitors
1
2016
216
0.030
 Why?
Radiotherapy Planning, Computer-Assisted
1
2015
118
0.030
 Why?
Radiotherapy
1
2015
177
0.030
 Why?
Organ Size
1
2015
434
0.030
 Why?
Postoperative Period
1
2015
292
0.030
 Why?
Nitriles
1
2015
152
0.030
 Why?
Demography
1
2015
261
0.030
 Why?
Radiotherapy, Intensity-Modulated
1
2015
123
0.030
 Why?
Recurrence
1
2017
952
0.030
 Why?
STAT5 Transcription Factor
1
2014
44
0.030
 Why?
Drug Interactions
1
2015
347
0.030
 Why?
Gonadotropin-Releasing Hormone
1
2015
193
0.030
 Why?
Longitudinal Studies
1
2020
2420
0.030
 Why?
Medication Adherence
1
2017
538
0.030
 Why?
Proportional Hazards Models
1
2015
1087
0.030
 Why?
ErbB Receptors
1
2015
557
0.030
 Why?
Cell Survival
1
2015
1024
0.030
 Why?
Double-Blind Method
1
2016
1659
0.030
 Why?
Biomarkers
1
2022
3468
0.020
 Why?
T-Lymphocytes, Regulatory
1
2014
342
0.020
 Why?
Molecular Targeted Therapy
1
2014
348
0.020
 Why?
Enzyme Inhibitors
1
2014
757
0.020
 Why?
Proto-Oncogene Proteins
1
2014
609
0.020
 Why?
Cell Cycle Proteins
1
2014
553
0.020
 Why?
Logistic Models
1
2015
1856
0.020
 Why?
Animals
2
2020
32102
0.020
 Why?
Mice
1
2020
15052
0.010
 Why?
Adolescent
1
2020
17903
0.010
 Why?
Signal Transduction
1
2014
4541
0.010
 Why?
Lam's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Expand Description
See all (249) concept(s)
_
Co-Authors Expand Description
See all (38) people
_
Similar People Expand Description
See all (60) people
_
Same Department Expand Description
Search Department
Physical Neighbors Expand Description
_

Copyright © 2025 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)